Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Sequential AmBisome vs Standard Daily Dosing in Febrile Neutropenia
NCT00421187Phase 4Terminated
- Sponsor
- Gilead Sciences
- Start
- Mar 2007
- Primary completion
- Apr 2008
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of liposomal amphotericin b in febrile neutropenia (FN), sponsored by Gilead Sciences. Started Mar 2007; status: terminated.
02
Drugs
liposomal amphotericin b
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT00421187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421187.